Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151082 | 0.90 | TSHR (0.68) | CYP2C19KMT2AMEN1NPC1KDM1A | |
| SCHEMBL2960872 | 0.83 | CYP2C19 (0.78) | CYP2C19KMT2ACRHBPCRHR2TSHR | |
| SCHEMBL5992560 | 0.83 | MEN1 (0.53) | KMT2AMEN1NPC1KDM1ACRHBP | |
| SCHEMBL11412127 | 0.82 | TSHR (0.68) | CYP2C19KMT2AMEN1NPC1KDM1A | |
| SCHEMBL153227 | 0.81 | MEN1 (0.51) | KMT2AMEN1NPC1CRHBPCRHR2 | |
| SCHEMBL3966210 | 0.79 | CYP2C19 (0.56) | CYP2C19KMT2ATSHRNR3C1ALDH1A1 | |
| Nitrogen SCHEMBL4599425 | 0.79 | TSHR (0.68) | CYP2C19KMT2ACRHBPCRHR2TSHR | |
| SCHEMBL1925493 | 0.79 | NPC1 (0.73) | KMT2AMEN1NPC1KDM1ACRHBP | |
| SCHEMBL43183 | 0.79 | TSHR (0.74) | CYP2C19KMT2ACRHBPCRHR2TSHR | |
| SCHEMBL6795389 | 0.79 | MAOB (0.64) | KMT2AMEN1NPC1MAOBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119613328-A | NAMPT inhibitor, composition, preparation method and application | 南华大学附属第一医院 | 2025-03-14 | — | — | CN | disclosed |
| US-9266879-B2 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTIC LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-9266879-B2 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTIC LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| EP-2563788-B1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE-INFLAMMATORY DISEASES | KARUS THERAPEUTICS LTD (GB) | 2015-08-05 | — | — | EP | disclosed |
| CN-103333275-B | With the polymkeric substance of functionalized with nitrile compounds comprising protected amino | BRIDGESTONE CO., LTD. (JP) | 2015-07-29 | — | — | CN | disclosed |
| CN-102985421-B | Naphthridine derivatives as pi3k inhibitors for the treatment of cancer and immune - inflammatory diseases | KARUS THERAPEUTICS LTD | 2014-12-24 | — | — | CN | disclosed |
| US-8735494-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| CN-103333275-A | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORP | 2013-10-02 | — | — | CN | disclosed |
| CN-102361887-B | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORP | 2013-06-26 | — | — | CN | disclosed |
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTICS LIMITED (UK) | 2013-05-02 | — | — | US | disclosed |
| US-20130085227-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2013-04-04 | — | — | US | disclosed |
| CN-102985421-A | Naphthridine derivatives as pi3k inhibitors for the treatment of cancer and immune - inflammatory diseases | KARUS THERAPEUTICS LTD | 2013-03-20 | — | — | CN | disclosed |
| EP-2563788-A1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES | Karus Therapeutics Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| US-8344066-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20120059112-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS COMTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| CN-102361887-A | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORP | 2012-02-22 | — | — | CN | disclosed |
| WO-2011135351-A1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES | KARUS THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| EP-2382240-A2 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | Bridgestone Corporation (JP) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010085622-A9 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010085622-A2 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | PIK3R5, PIK3CA, NFKBIA | CYP2C19 1154/4885KMT2A 3106/4885MEN1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.